Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $67,361.76 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 3,348 shares of Travere Therapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $20.12, for a total transaction of $67,361.76. Following the sale, the chief accounting officer now directly owns 63,654 shares in the company, valued at approximately $1,280,718.48. This trade represents a 5.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, January 22nd, Sandra Calvin sold 925 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.94, for a total transaction of $17,519.50.
• On Thursday, December 26th, Sandra Calvin sold 15,000 shares of Travere Therapeutics stock. The shares were sold at an average price of $17.22, for a total transaction of $258,300.00.
• On Monday, November 25th, Sandra Calvin sold 12,090 shares of Travere Therapeutics stock. The stock was sold at an average price of $18.30, for a total transaction of $221,247.00.

Travere Therapeutics Trading Up 3.1 %

Travere Therapeutics stock opened at $21.86 on Friday. Travere Therapeutics, Inc. has a fifty-two week low of $5.12 and a fifty-two week high of $22.13. The firm has a 50 day moving average price of $18.80 and a 200 day moving average price of $15.56. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on TVTX shares. Cantor Fitzgerald started coverage on Travere Therapeutics in a report on Friday, January 10th. They issued an “overweight” rating for the company. Barclays lifted their price target on Travere Therapeutics from $18.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 1st. Piper Sandler boosted their price target on shares of Travere Therapeutics from $12.00 to $22.00 and gave the company a “neutral” rating in a research report on Thursday, November 14th. Scotiabank raised their price objective on shares of Travere Therapeutics from $23.00 to $27.00 and gave the stock a “sector outperform” rating in a research report on Friday, November 1st. Finally, HC Wainwright increased their price target on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $24.00.

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the company. Jennison Associates LLC purchased a new stake in Travere Therapeutics during the fourth quarter worth about $14,222,000. abrdn plc purchased a new position in Travere Therapeutics in the fourth quarter worth approximately $6,829,000. Emerald Advisers LLC grew its stake in shares of Travere Therapeutics by 19.8% during the third quarter. Emerald Advisers LLC now owns 1,960,659 shares of the company’s stock worth $27,430,000 after purchasing an additional 323,513 shares in the last quarter. Impax Asset Management Group plc acquired a new position in shares of Travere Therapeutics during the 4th quarter worth about $5,226,000. Finally, Emerald Mutual Fund Advisers Trust increased its stake in Travere Therapeutics by 26.0% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 1,185,709 shares of the company’s stock valued at $16,588,000 after purchasing an additional 244,444 shares during the last quarter.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.